Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

Table 4 Cardiovascular benefits of GLP-1 agonists

Trial	Agents	MACEs (HR/p)	CV death (HR/p)	HF (HR/p)	Renal outcome (HR/P)
ELIXA	Lixisenatide	1.02/0.78	0.98/0.85	0.96/0.75	0.84/0.083
LEADER3	Liraglutide	0.87/0.01	0.98/0.85	0.87/0.14	0.78/0.003
SUSTAIN-6	Semaglutide	0.74/0.016	0.98/0.92	1.11/0.57	0.64/0.005
EXSCEL	Exenatide	0.91/0.061	0.88/0.096	0.94/0.49	0.88/0.065
REWIND	Dulaglutide	0.88/0.026	0.91/0.21	0.93/0.46	0.85/0.0004
HARMONY	Albiglutide	0.78/0.0006	0.93/0.58	0.71/0.019	#
AMPLITUDE-O	Efpeglenatide	0.73/0.0069	0.72/0.07	0.61/0.04	0.68/ < 0.0001

p p values, # missing data, MACE major adverse cardiac events, HR hazard ratio, CV cardiovascular, HF heart failure

ISSN: 1475-2840